Kairos Pharma KAPA
NYSE KAPA
$0.55 +0.01 (+1.05%)
As of: Oct 23, 2026 · 3:59 PM EDT

Kairos Pharma (KAPA) Return on Capital Employed [ROCE] (2024 - 2025)

Updated

Kairos Pharma (KAPA) reported Return on Capital Employed [ROCE] of -93.57% for FY2025, up 5.10 percentage points from -98.67% in FY2024.

Analysis

Kairos Pharma (KAPA) Return on Capital Employed [ROCE] (2024 - 2025) Analysis & Trends

  • According to Business Quant data, Return on Capital Employed [ROCE] came in at -98.67% in FY2024.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) ROCE (Qtr)
1 Eli Lilly 1,137.66 Bn 1,106.24 Bn 19.71 Bn 46.74%
2 Johnson & Johnson 636.13 Bn 556.00 Bn 17.30 Bn 17.52%
3 AbbVie 505.28 Bn 478.39 Bn 12.70 Bn 17.92%
4 Merck 358.10 Bn 312.48 Bn 12.21 Bn 6.28%
5 Novartis Ag 292.59 Bn 256.58 Bn 11.24 Bn 19.32%
6 Astrazeneca 265.81 Bn 239.50 Bn 12.86 Bn 16.76%
7 Amgen 237.53 Bn 192.93 Bn 7.24 Bn 16.66%
8 Gilead Sciences 194.67 Bn 168.86 Bn 6.22 Bn -5.97%
9 Pfizer 171.17 Bn 117.82 Bn 10.94 Bn 11.86%
10 Kairos Pharma 10.50 Mn -1.91 Mn - -
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2025 -68.65%
Mar 31, 2025 -54.85%
Dec 31, 2024 -53.21%
API Access

Kairos Pharma Return on Capital Employed [ROCE] API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=return-on-capital-employed-%5Broce%5D&ticker=KAPA&period=max&api_key=YOUR_API_KEY